Figure 4
From: Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
GeparQuinto study design for HER2-negative cohort. B, bevacizumab (15 mg/kg intravenously: day 1 q day 21 for eight cycles); C, cyclophosphamide (600 mg/m2: day 1 q day 21 for four cycles); CR, complete response; E, epirubicin (90 mg/m2: every 3 weeks for four cycles); Her-2, human epidermal growth factor receptor 2; NC, no change; PR, partial response; Pw, paclitaxel weekly (80 mg/m2: weekly for 12 weeks total); Pw + R, paclitaxel weekly + RAD001 (5 mg daily); R, randomisation; T, docetaxel (100 mg/m2: day 1 q day 21 for four cycles). Reprinted with permission from GBG (German Breast Group).